Loading...
Loading...
ENSC| Name | Value |
|---|---|
| Revenues | 305.7K |
| Cost of Revenue | 778.9K |
| Gross Profit | -473.0K |
| Operating Expense | 1,370.0K |
| Operating I/L | -1,843.0K |
| Other Income/Expense | -1,274.0K |
| Interest Income | 0.0K |
| Pretax | -3,117.0K |
| Income Tax Expense | -0.1K |
| Net Income/Loss | -3,116.0K |
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing abuse-resistant opioid prodrugs for severe pain relief and overdose protection. The company's products include PF614, a TAAP prodrug candidate of oxycodone for acute and chronic pain treatment; PF614-MPAR, a combination product for overdose protection; PF329, an extended-release prodrug of hydromorphone; PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder.
